Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 1, January, p. 157–163

doi: 10.17219/acem/112613

Publication type: review article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Palmoplantar pustulosis: Factors causing and influencing the course of the disease

Magdalena Putra-Szczepaniak1,A,C,D, Joanna Maj1,B,C,E, Alina Jankowska-Konsur1,B,C,E, Anna Czarnecka2,3,C,D, Anita Hryncewicz-Gwóźdź1,A,C,D,F

1 Clinic of Dermatology, Venereology and Allergology, Wroclaw Medical University, Poland

2 Regional Specialist Hospital, Research and Development Centre, Wrocław, Poland

3 Faculty of Physiotherapy, University School of Physical Education, Wrocław, Poland

Abstract

Palmoplantar pustulosis (PPP) is a chronic inflammatory disease, most often occurring in middle-aged women. In the course of the condition, painful skin lesions appear on the hands and feet, i.e., areas that are extremely important in everyday life. Therefore, the disease significantly reduces quality of life. The pathogenesis of this disease is poorly understood, although it is known that genetic, immunological and environmental factors play a role in its development. Clinical observations confirm the role of nicotine and contact allergens in the development of the lesions. The skin lesions can also occur as a side effect of certain medications. In some cases, PPP coexists with other diseases, i.e., seronegative arthropathies, as well as celiac and thyroid diseases. There is also a connection between the disease and infectious bacterial foci. Exacerbation of the skin lesions is triggered by stress. Therefore, patients require multidirectional tests, since finding the cause of the disease is essential to administering effective treatment.

Key words

etiopathogenesis, palmoplantar pustulosis, exacerbating factors

References (55)

  1. Yamamoto T. Extra-palmoplantar lesions associated with palmoplantar pustulosis. J Eur Acad Dermatol Venereol. 2009;23(11):1227–1232.
  2. Ammoury A, El Sayed F, Dhaybi R, Bazex J. Palmoplantar pustulosis should not be considered as a variant of psoriasis. J Eur Acad Dermatol Venereol. 2008;22(3):392–393.
  3. de Waal AC, van de Kerkhof PC. Pustulosis palmoplantaris is a disease distinct from psoriasis. J Dermatolog Treat. 2011;22(2):102–105.
  4. Murakami M, Ohtake T, Horibe Y, et al. Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. J Invest Dermatol. 2010;130(8):2010–2016.
  5. Hagforsen E, Michaëlsson G, Stridsberg M. Normal and PPP-affected palmoplantar sweat gland express neuroendocrine markers chromogranins and synaptophysin differently. Arch Dermatol Res. 2010;302(9):685–693.
  6. Eriksson MO, Hagforsen E, Lundin IP, Michaëlsson G. Palmoplantar pustulosis: A clinical and immunohistological study. Br J Dermatol. 1998;138(3):390–398.
  7. Allen MH, Ameen H, Veal C, et al. The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. J Invest Dermatol. 2005;124(1):103–106.
  8. Asumalahti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol. 2003;120(4):627–632.
  9. Szanto E, Linse U. Arthropathy associated with palmoplantar pustulosis. Clin Rheumatol. 1991;10(2):130–135.
  10. Douroudis K, Kingo K, Traks T, et al. ATG16L1 gene polymorphisms are associated with palmoplantar pustulosis. Hum Immunol. 2011;72(7):613–615.
  11. Wang TS, Chiu HY, Hong JB, Chan CC, Lin SJ, Tsai TF. Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients. Arch Dermatol Res. 2016;308(1):55–63.
  12. Nakai N, Sugiura K, Akiyama M, Katoh N. Acute generalized exanthematous pustulosis caused by dihydrocodeine phosphate in a patient with psoriasis vulgaris and a heterozygous IL36RN mutation. JAMA Dermatol. 2015;151(3):311–315.
  13. Hagforsen E, Hedstrand H, Nyberg F, Michaëlsson G. Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis. Br J Dermatol. 2010;163(3):572–579.
  14. Murakami M, Hagforsen E, Morhenn V, Ishida-Yamamoto A, Iizuka H. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011;20(10):845–847.
  15. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130(5):1373–1383.
  16. Croxford AL, Karbach S, Kurschus FC, et al. IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions. J Invest Dermatol. 2014;134(3):728–735.
  17. Bissonnette R, Nigen S, Langley RG, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmoplantar (PP) pustular psoriasis or PP pustulosis: Results from a randomised controlled trial. J Eur Acad Dermatol Venereol. 2014;28(10):1298–1305.
  18. Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev. 2011;22(2):83–89.
  19. Rincon M. Interleukin-6: From an inflammatory marker to a target for inflammatory diseases. Trends Immunol. 2012;33(11):571–577.
  20. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121(9):3375–3383.
  21. Miyoshi K, Takaishi M, Nakajima K, et al. Stat3 as a therapeutic target for the treatment of psoriasis: A clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol. 2011;131(1):108–117.
  22. Ataie-Kachoie P, Pourgholami MH, Morris DL. Inhibition of the IL-6 signaling pathway: A strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev. 2013;24(2):163–173.
  23. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002;13(4–5):357–368.
  24. Romano M, Sironi M, Toniatti, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997;6(3):315–325.
  25. Bartoccioni E, Scuderi F, Marino M, Provenzano C. IL-6, monocyte infiltration and parenchymal cells. Trends Immunol. 2003;24(6):299–300.
  26. Blumberg H, Dinh H, Dean C Jr, et al. IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J Immunol. 2010;185(7):4354–4362.
  27. Tortola L, Rosenwald E, Abel B, et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest. 2012;122(11):3965–3976.
  28. Johnston A, Xing X, Guzman AM, et al. IL-1F5, -F6, -F8, and -F9: A novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol. 2011;186(4):2613–2622.
  29. Skov L, Beurskens FJ, Zachariae CO, et al. IL-8 as antibody therapeutic target in inflammatory diseases: Reduction of clinical activity in palmoplantar pustulosis. J Immunol. 2008;181(1):669–679.
  30. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620–628.
  31. Tripodi D, Conti F, Rosati et al. IL-36 a new member of the IL-1 family cytokines. J Biol Regul Homeost Agents. 2012;26(1):7–14.
  32. Carrier Y, Ma HL, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: Implications in psoriasis pathogenesis. J Invest Dermatol. 2011;131(12):2428–2437.
  33. Capon F. IL36RN mutations in generalized pustular psoriasis: Just the tip of the iceberg? J Invest Dermatol. 2013;133(11):2503–2504.
  34. Elahmed HH. Rapid improvement of palmoplantar psoriasis after cessation of smoking. Sultan Qaboos Univ Med J. 2013;13(1):188–189.
  35. Caca-Biljanovska N, V’lckova-Laskoska M, Balabanova-Stefanova M, Grivceva-Panovska V. Frequency of delayed-type hypersensitivity to contact allergens in palmoplantar psoriasis. Prilozi. 2005;26(2):131–141.
  36. Ito T, Mori T, Fujiyama T, Tokura Y. Dramatic exacerbation of palmoplantar pustulosis following strongly positive nickel patch testing. Int J Dermatol. 2014;53(5):e327–e329.
  37. Bordel-Gómez MT, Sánchez-Estella J, Martínez-González O, Cardeñoso-Alvarez ME. Palmoplantar psoriasis: A paradoxical adverse reaction induced by adalimumab. J Eur Acad Dermatol Venereol. 2009;23(4):444–445.
  38. Hagforsen E, Michaëlsson K, Lundgren E, et al. Women with palmoplantar pustulosis have disturbed calcium homeostasis and a high prevalence of diabetes mellitus and psychiatric disorders: A case-control study. Acta Derm Venereol. 2005;85(3):225–232.
  39. Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: The Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012;67(5):e179–e185.
  40. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action. Arthritis Rheum. 2008;59(7):996–1001.
  41. Bordel-Gómez MT, Sánchez-Estella J, Martínez-González O, Cardeñoso-Alvarez ME. Palmoplantar psoriasis: A paradoxical adverse reaction induced by adalimumab. J Eur Acad Dermatol Venereol. 2009;23(4):444–445.
  42. Kobayashi S. Tonsil-related skin diseases and possible involvement of T cell co-stimulation in chronic focal infection. Adv Otorhinolaryngol. 2011;72:83–85.
  43. Tsuboi H, Katsuoka K. Pustulosis palmaris et plantaris with prominent hyperkeratosis of the soles. J Dermatol. 2006;33(12):892–895.
  44. Takahara M. Clinical outcome of tonsillectomy for palmoplantar pustulosis and etiological relationship between palmoplantar pustulosis and tonsils. Adv Otorhinolaryngol. 2011;72:86–88.
  45. Quint KD, van der Helm-van Mil AH, Bergman W, Lavrijsen AP. Mucocutaneous abnormalities in Chlamydia trachomatis-induced reactive arthritis [in Dutch]. Ned Tijdschr Geneeskd. 2010;154:A1614
  46. Jansen CT, Hollmén, Pajarre R, Terho P. Antichlamydial antibodies in chronic palmoplantar pustulosis. Acta Derm Venereol. 1980;60(3):263–266.
  47. Martin Hübner A, Tenbaum SP. Complete remission of palmoplantar psoriasis through Helicobacter pylori eradication: A case report. Clin Exp Dermatol. 2008;33(3):339–340.
  48. Sáez-Rodríguez M, Noda-Cabrera A, Alvarez-Tejera S, et al. The role of psychological factors in palmoplantar pustulosis. J Eur Acad Dermatol Venereol. 2002;16(4):325–327.
  49. Michaëlsson G, Kristjánsson G, Pihl Lundin I, Hagforsen E. Palmoplantar pustulosis and gluten sensitivity: A study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet. Br J Dermatol. 2007;156(4):659–666.
  50. Weisenseel P, Kuznetsov AV, Ruzicka T, Prinz JC. Palmoplantar pustulosis is not inevitably associated with antigliadin antibodies. Br J Dermatol. 2007;156(6):1399–1400.
  51. Károlyi Z, Harhai I, Erós N. Dermatologic aspects of SAPHO-syndrome. Orv Hetil. 2001;142(33):1801–1804.
  52. Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. Acne-pustulosis-hyperostosis-osteitis syndrome: Results of a national survey (85 cases). Rev Rhum Mal Osteoartic. 1987;54(3):187–196.
  53. Stanford CW, Kollipara R, Melookaran AM, Hall JC. Palmoplantar pustular psoriasis following initiation of a beta-blocker: Disease control with low-dose methotrexate. Cutis. 2014;94(3):153–155.
  54. Matzaroglou Ch, Velissaris D, Karageorgos A, Marangos M, Panagiotopoulos E, Karanikolas M. SAPHO Syndrome diagnosis and treatment: Report of five cases and review of the literature. Open Orthop J. 2009;3:100–106.
  55. Giménez-García R, Sánchez-Ramón S, Cuellar-Olmedo LA. Palmoplantar pustulosis: A clinicoepidemiological study. The relationship between tobacco use and thyroid function. J Eur Acad Dermatol Venereol. 2003;17(3):276–279.